110 related articles for article (PubMed ID: 35245746)
1. A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort.
Gunda A; Basavaraj C; Serkad V CP; Adinarayan M; Kolli R; Siraganahalli Eshwaraiah M; Saura C; Ruiz F; Gomez P; Peg V; Jimenez J; Sprung S; Fiegl H; Brunner C; Egle D; Bhattacharyya GS; Bakre MM
Breast; 2022 Jun; 63():1-8. PubMed ID: 35245746
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.
Bakre MM; Ramkumar C; Attuluri AK; Basavaraj C; Prakash C; Buturovic L; Madhav L; Naidu N; R P; Somashekhar SP; Gupta S; Doval DC; Pegram MD
Cancer Med; 2019 Apr; 8(4):1755-1764. PubMed ID: 30848103
[TBL] [Abstract][Full Text] [Related]
3. The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin.
Chandra Doval D; Mehta A; Somashekhar SP; Gunda A; Singh G; Bal A; Khare S; Prakash V Serkad C; Adinarayan M; Krishnamoorthy N; Vijay DG; Anantakrishnan R; Bhattacharyya GS; Bakre MM
Breast; 2021 Oct; 59():1-7. PubMed ID: 34098459
[TBL] [Abstract][Full Text] [Related]
4. Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial.
Zhang X; Gunda A; Kranenbarg EM; Liefers GJ; Savitha BA; Shrivastava P; Serkad CPVK; Kaur T; Eshwaraiah MS; Tollenaar RAEM; van de Velde CJH; Seynaeve CMJ; Bakre M; Kuppen PJK
Breast Cancer Res; 2023 Apr; 25(1):40. PubMed ID: 37060036
[TBL] [Abstract][Full Text] [Related]
5. Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients.
Attuluri AK; Serkad CPV; Gunda A; Ramkumar C; Basavaraj C; Buturovic L; Madhav L; Naidu N; Krishnamurthy N; Prathima R; Kanaldekar S; Bakre MM
BMC Cancer; 2019 Mar; 19(1):249. PubMed ID: 30894144
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of recurrence risk predictions in ER+/HER2- early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast.
Gunda A; Eshwaraiah MS; Gangappa K; Kaur T; Bakre MM
Breast Cancer Res Treat; 2022 Nov; 196(2):299-310. PubMed ID: 36085534
[TBL] [Abstract][Full Text] [Related]
7. The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment.
Eshwaraiah MS; Gunda A; Kanakasetty GB; Bakre MM
Cancer Med; 2023 Jun; 12(12):13342-13351. PubMed ID: 37245224
[TBL] [Abstract][Full Text] [Related]
8. Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.
Sengupta AK; Gunda A; Malpani S; Serkad CPV; Basavaraj C; Bapat A; Bakre MM
Cancer Med; 2020 Nov; 9(21):7810-7818. PubMed ID: 33027559
[TBL] [Abstract][Full Text] [Related]
9. CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario.
Sankaran S; Dikshit JB; Prakash Sv C; Mallikarjuna SE; Somashekhar SP; Patil S; Kumar R; Prasad K; Shet D; Bakre MM
Indian J Surg Oncol; 2021 Apr; 12(Suppl 1):21-29. PubMed ID: 33994724
[TBL] [Abstract][Full Text] [Related]
10. Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer.
Ramkumar C; Buturovic L; Malpani S; Kumar Attuluri A; Basavaraj C; Prakash C; Madhav L; Doval DC; Mehta A; Bakre MM
Biomark Insights; 2018; 13():1177271918789100. PubMed ID: 30083053
[TBL] [Abstract][Full Text] [Related]
11. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
12. Validation of CanAssist Breast immunohistochemistry biomarkers on an automated platform and its applicability in tissue microarray.
Serkad CPV; Attuluri AK; Basavaraj C; Adinarayan M; Krishnamoorthy N; Ananthamurthy SB; Mallikarjuna SE; Bakre MM
Int J Clin Exp Pathol; 2021; 14(10):1013-1021. PubMed ID: 34760037
[TBL] [Abstract][Full Text] [Related]
13. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract][Full Text] [Related]
14. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
15. Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.
Park YH; Im SA; Cho EY; Ahn JH; Woo SY; Kim S; Keam B; Lee JE; Han W; Nam SJ; Park IA; Noh DY; Yang JH; Ahn JS; Im YH
Oncology; 2014; 86(5-6):279-88. PubMed ID: 24903080
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
18. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
